33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Changes of the mutational landscape in relapsed acute myeloid leukemia
    Meeting Abstract

    Rapaport, F.; de Massy, M. R.; al Hinai, A.; Sanders, M. A.; Hricik, T.; Sheridan, C.; Lee, T. C.; Neelamraju, Y.; Patel, J.; Chung, S. S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Third party CMV-specific cytotoxic T cells for treatment of antiviral resistant CMV infection after hematopoietic stem cell transplant
    Meeting Abstract

    Prockop, S.; Doubrovina, E.; Hasan, A. N.; Dahi, P. B.; Giralt, S.; Koehne, G.; Kernan, N. A.; Papadopoulos, E. B.; Lehrman, R.; Rodriguez-Sanchez, I.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Loss of adrenergic nerves in the bone marrow microenvironment drives an aging HSC niche phenotype
    Meeting Abstract

    Maryanovich, M.; Zahalka, A. H.; Pierce, H.; Pinho, S.; Nakahara, F.; Asada, N.; Leftin, A.; Vijg, J.; Frenette, P. S.
    Blood (2016)

    Fulltext@MSK | Save
  • Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL
    Meeting Abstract

    Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
    Blood (2016)

    Fulltext@MSK | Save
  • Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, phase 2 study
    Meeting Abstract

    Noy, A.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Collins, G. P.; Ma, S.; Coleman, M.; Peles, S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
    Meeting Abstract

    Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V. E.; Hendrickson, R.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
    Blood (2016)

    Fulltext@MSK | Save
  • Predictive value of mutation analysis in the diagnostic approach to patients with unexplained cytopenia
    Meeting Abstract

    Malcovati, L.; Gallì€, A.; Travaglino, E.; Ambaglio, I.; Rizzo, E.; Molteni, E.; Elena, C.; Catricalà€, S.; Bono, E.; Bianchessi, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): Final results of the SWOG/Alliance/ECOG S0535 trial
    Meeting Abstract

    Lancet, J. E.; Moseley, A.; Komrokji, R. S.; Coutre, S. E.; DeAngelo, D. J.; Tallman, M. S.; Litzow, M.; Othus, M.; Appelbaum, F. R.
    Blood (2016)

    Fulltext@MSK | Save
  • Organ biomarker responses in patients with light chain amyloidosis treated with NEOD001 are independent of previous hematologic response
    Meeting Abstract

    Liedtke, M.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Walling, J.; Kinney, G. G.; Koller, M.; Schenk, D. B.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health
    Meeting Abstract

    List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; more...
    Blood (2016)

    Fulltext@MSK | Save